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background
 
In women 70 years of age or older who have early breast cancer, it is unclear whether
lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus
radiation therapy.
 
methods
 
Between July 1994 and February 1999, we randomly assigned 636 women who were 70
years of age or older and who had clinical stage I (T1N0M0 according to the tumor–
node–metastasis classification), estrogen-receptor–positive breast carcinoma treated
by lumpectomy to receive tamoxifen plus radiation therapy (317 women) or tamoxifen
alone (319 women). Primary end points were the time to local or regional recurrence,
the frequency of mastectomy for recurrence, breast-cancer–specific survival, the time
to distant metastasis, and overall survival.
 
results
 
The only significant difference between the two groups was in the rate of local or re-
gional recurrence at five years (1 percent in the group given tamoxifen plus irradiation
and 4 percent in the group given tamoxifen alone, P<0.001). There were no significant
differences between the two groups with regard to the rates of mastectomy for local re-
currence, distant metastases, or five-year rates of overall survival (87 percent in the
group given tamoxifen plus irradiation and 86 percent in the tamoxifen group,
P=0.94). Assessment by physicians and patients of cosmetic results and adverse events
uniformly rated tamoxifen plus irradiation inferior to tamoxifen alone.
 
conclusions
 
Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the
treatment of women 70 years of age or older who have early, estrogen-receptor–
positive breast cancer.
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ultiple trials of breast-con-
 
serving surgery for breast cancer
 
1-5
 
 have
shown that postoperative irradiation
decreases the rate of ipsilateral recurrence but of-
fers no survival benefit. However, the high rate of
recurrence with surgery alone (10 to 40 percent)
has suggested that the only two appropriate treat-
ments are modified radical mastectomy and breast-
conserving surgery plus adjuvant radiation therapy.
Since tamoxifen, with
 
3
 
 or without
 
4
 
 radiation thera-
py, decreases the risk of recurrence, and given the
cost and adverse effects of breast irradiation
 
5-12
 
and its negative effect on the quality of life,
 
6,7
 
 we
designed a trial to determine whether women 70
years of age or older who have early, estrogen-
receptor–positive breast cancer can be safely treat-
ed with tamoxifen alone instead of irradiation plus
tamoxifen. Such women were selected for the trial
because they have a lower rate of recurrence
 
8-16
 
and a shorter time at risk for recurrence than
younger women.
The study (C9343) was designed by the Cancer and
Leukemia Group B (CALGB) in cooperation with the
Eastern Cooperative Oncology Group (ECOG) and
the Radiation Therapy Oncology Group (RTOG).
The protocol was approved by each local institu-
tional review board and complied with the Declara-
tion of Helsinki. Written informed consent was ob-
tained from all participants with the use of consent
forms approved by each local institutional review
board. Study oversight was provided by an indepen-
dent data and safety monitoring committee.
Data collection was managed by the CALGB
Statistical Center. Data quality was ensured by re-
view of data by staff members of the CALGB Statis-
tical Center and by the study chairperson. CALGB
statisticians performed the statistical analyses.
Under the CALGB quality-assurance program,
members of the data audit committee visit all par-
ticipating institutions at least every three years to
review source documents. The auditors verify com-
pliance with federal regulations and protocol re-
quirements. Such on-site review of medical records
was performed for 105 patients (16 percent) en-
rolled in this study.
 
patient selection
 
Eligible subjects were women 70 years of age or old-
er who had clinical stage I breast cancer (T1N0M0
according to the tumor–node–metastasis classifica-
tion system) and no history of cancer other than in
situ cervical cancer or nonmelanoma skin cancer
within five years before randomization. When the
trial began in July 1994, the eligibility criteria in-
cluded a tumor with a diameter of no more than
4 cm (T1 or T2), regardless of estrogen-receptor
status. In August 1996, in an attempt to broaden
participation by physicians concerned about the
upper size limit, the eligible tumor size was reduced
to 2 cm or less (T1) and estrogen-receptor status
was required to be positive or unknown. Patients
had to have undergone a lumpectomy with nega-
tive margins (defined by the absence of tumor at
the inked pathological margins) and to have been
node-negative on clinical assessment.
 
treatment
 
At study entry patients were randomly assigned, in
a 1:1 ratio, to receive tamoxifen alone or with radi-
ation therapy. Randomization was performed by
the CALGB Statistical Center with the use of a shuf-
fling algorithm by Knuth.
 
14
 
 Patients were stratified
according to age (less than 75 years vs. 75 years or
more) and whether axillary dissection was per-
formed (yes vs. no). Randomization of the CALGB
and RTOG patients was handled by the CALGB Sta-
tistical Center, and randomization of the ECOG pa-
tients was handled by the ECOG Randomization
Desk with the use of the same algorithm and strat-
ification scheme. Patients were followed every four
months for five years, then yearly thereafter.
 
Local Therapy
 
All women underwent lumpectomy (i.e., partial
mastectomy or a wide local excision) with a clear
margin, defined by the absence of tumor on the
inked pathological margins. Axillary-node dissec-
tion was allowed but was discouraged.
Among the women who were randomly as-
signed to receive radiation therapy, the entire ipsi-
lateral breast was treated, with tangential fields.
The 45-Gy dose was given in 25 daily fractions of
1.8 Gy, delivered by means of either cobalt-60 gam-
ma rays or a linear accelerator with a maximal ener-
gy of 6-MV photons. The planning volume includ-
ed a 1-cm margin to allow for motion and included
the area of lower axillary lymph nodes (levels I and
II). Corner blocks were permitted only at the inferi-
or deep border. The maximal width of the lung in
the tangential fields was 3 cm. Breast irradiation
was followed by an electron boost to the primary
m
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site of up to 14 Gy, given in seven fractions of 2 Gy
per day. The electron boost was given to a shaped
field that included the area of the tumor bed with a
2-cm margin in all directions. The dose was not ad-
justed for the heterogeneity of tissue. Wedge com-
pensators were used to achieve a uniform dose.
 
Tamoxifen
 
All women received 20 mg of tamoxifen per day for
five years.
 
9,10
 
 Tamoxifen was begun during or after
radiation therapy at the discretion of the treating
physician.
 
study end points
 
The primary study end points were the time to local
or regional recurrence, the frequency of mastectomy
for recurrence, breast-cancer–specific survival, the
time to distant metastasis, and overall survival. Lo-
cal or regional recurrence was defined as any recur-
rence in the supraclavicular, infraclavicular, and ip-
silateral axillary nodes, as well as any recurrence in
the ipsilateral breast.
Secondary end points were the cosmetic result
and adverse effects and were assessed at baseline
and at the four-month, one-year, two-year, and four-
year follow-up visits. Both physicians and patients
compared the affected and unaffected breasts with
regard to the range of motion of the arm and shoul-
der, arm and breast swelling, breast and chest-wall
pain, skin-color changes, fibrosis or retraction, and
cosmesis. Cosmesis was scored on a four-point
scale, with 1 indicating excellent results and 4 poor
results. The other adverse effects (breast pain,
shoulder pain, arm or shoulder stiffness, arm ede-
ma, breast edema, skin-color changes, and fibrosis
and retraction of the breast) were rated on a four-
point scale, with 1 indicating no difference between
the affected and unaffected breasts and 4 indicat-
ing that the affected breast was much worse than
the unaffected breast.
 
statistical analysis
 
To determine sample size when the study was
planned, we used the results of the two large pub-
lished randomized trials that were available (Na-
tional Surgical Adjuvant Breast and Bowel Project
Study B-04 for axillary recurrence
 
11
 
 and Study B-06
for breast recurrence), knowing that both had ex-
cluded women over the age of 70 years (we could
not assume that the risk of local or regional recur-
rence would be lower in older women, since there
were no definitive data to support this assump-
tion). Power calculations were based on the time to
local or regional recurrence. The three-year rate of
local or regional recurrence was expected to be 16
percent among women treated with tamoxifen
alone and 9 percent among women treated with ta-
moxifen plus irradiation. The enrollment of 572
women over a period of 38 months was required
for the study to have a statistical power of 90 per-
cent to detect this difference, assuming a one-sided
significance level of 5 percent and assuming that
follow-up continued for 4 years after enrollment
ended. P values and confidence intervals were de-
termined with use of O’Brien–Fleming boundaries
with a Lan–DeMets spending function on the basis
of these four analysis points.
 
12
 
Distributions of time-to-event variables were
estimated according to the Kaplan–Meier meth-
od
 
15
 
 and distributions were compared between
treatment groups by means of the log-rank test.
 
16
 
For cosmetic and adverse-effect end points, at each
assessment, patients’ ratings in the two groups
 
* Race or ethnic group was reported by the investigators.
 
Table 1. Baseline Characteristics of the 636 Women.
Characteristic
Tamoxifen + Irradiation
(N=317)
Tamoxifen 
(N=319)
 
no. of women (%)
 
Stratification
 
Age
70–74 yr
≥75 yr
139 (44)
178 (56)
146 (46)
173 (54)
Axillary dissection
No
Yes
200 (63)
117 (37)
204 (64)
115 (36)
 
Demographic
 
Race or ethnic group*
White
Hispanic
Black
Asian
Other
Unknown
287 (91)
5 (2)
23 (7)
0 
1 (<1)
1 (<1)
287 (90)
8 (2)
22 (7)
2 (1)
0 
0 
Estrogen-receptor status
Negative
Positive
Unknown
6 (2)
308 (97)
3 (1)
4 (1)
310 (97)
5 (2)
Progesterone-receptor status
Negative
Positive
Unknown
56 (18)
251 (79)
10 (3)
67 (21)
245 (77)
7 (2)
Size of primary tumor
≤2 cm
>2 cm
312 (98)
5 (2)
310 (97)
9 (3)
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were compared with the use of the t-test for inde-
pendent samples. The process was repeated for phy-
sicians’ ratings. All P values are two-sided and un-
adjusted for multiplicity.
According to standard CALGB policy, formal
monitoring reports, including analysis of all study
end points, were submitted every six months to an
independent data and safety monitoring board.
The study was allowed to exceed its accrual goals
because of the smaller than expected number of
events. In October 2000, the data and safety moni-
toring board released the results for publication
when it became apparent that the event rate was
markedly lower than expected and that further de-
lay would have little effect on the ultimate differ-
ences in survival or breast recurrence.
Data are current as of September 2003. The me-
dian follow-up as of that date was five years.
The study was initiated by the CALGB in July 1994
and by the RTOG and ECOG in December 1996.
Enrollment ended in February 1999. A total of 647
women were enrolled: 307 by the CALGB, 112 by
the ECOG, and 228 by the RTOG. Eleven patients
(2 percent) never received the treatment outlined in
the protocol. Four patients (1 percent) were found
to be ineligible. Statistical analyses included 636
patients: 317 were randomly assigned to receive
tamoxifen plus irradiation and 319 to receive tamox-
ifen alone. Before the change in eligibility, 129 pa-
tients were enrolled; 10 of these 129 had estrogen-
receptor–negative tumors, and 14 had tumors that
were more than 2 cm in diameter. The baseline
characteristics of the women were similar in the
two groups (Table 1).
 
time to local or regional recurrence
 
As compared with the tamoxifen group, the group
given tamoxifen plus irradiation had a significantly
longer time to local or regional recurrence (breast
plus axilla) (P<0.001) (Fig. 1). Sixteen women in
the tamoxifen group had had a local or regional re-
currence (actuarial rate at five years, 4 percent); of
these, 13 had an ipsilateral recurrence only, 1 had
an ipsilateral recurrence with distant spread, and 2
had an axillary recurrence only (Table 2). Two wom-
en in the group given tamoxifen plus irradiation
had had a local or regional recurrence (actuarial
rate at five years, 1 percent); both were ipsilateral
recurrences. The five-year probability of freedom
from local or regional recurrence was 99 percent
(95 percent confidence interval, 98 to 100 percent)
in the group given tamoxifen plus irradiation and
96 percent (95 percent confidence interval, 93 to 98
percent) in the tamoxifen group.
 
time to mastectomy
 
The time to mastectomy after a recurrence did not
differ significantly between the two treatment
groups (P=0.15). After a recurrence in the ipsilat-
eral breast, two women in the group given tamoxi-
fen plus irradiation and six women in the tamoxi-
fen group underwent mastectomy. Eight women in
the tamoxifen group who had a recurrence in the
breast underwent lumpectomy (in seven it was fol-
lowed by breast irradiation), whereas the two wom-
en with an axillary recurrence in this group under-
went axillary dissection. The five-year probability
of not undergoing mastectomy was 99 percent (95
percent confidence interval, 98 to 100 percent) in
the group given tamoxifen plus irradiation and 98
percent (95 percent confidence interval, 97 to 100
percent) in the tamoxifen group.
 
time to distant metastasis
 
The time to distant metastasis did not differ signifi-
cantly between the two treatment groups (P=0.97);
distant relapse occurred in seven patients in each
group. The five-year probability of freedom from
distant recurrence was 99 percent (95 percent con-
fidence interval, 97 to 100 percent) in the group
given tamoxifen plus irradiation and 98 percent
(95 percent confidence interval, 97 to 100 percent)
in the tamoxifen group.
results
 
Figure 1. Time to First Local or Regional Recurrence.
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overall survival
 
Treatment was not significantly related to overall
survival (P=0.94): 54 women died in the group giv-
en tamoxifen plus radiation therapy, as compared
with 53 in the tamoxifen group (Table 2). Among
these 107 women, 6 died of breast cancer (3 in each
group). The probability of being alive at five years
was 87 percent (95 percent confidence interval, 84
to 91 percent) in the group given tamoxifen plus ir-
radiation and 86 percent (95 percent confidence in-
terval, 82 to 90 percent) in the tamoxifen group
(Fig. 2).
 
ratings of cosmetic results 
and adverse effects
 
Table 3 shows comparisons of cosmetic results and
adverse effects between the two treatment groups
as rated by physicians and patients. Physicians rat-
ed overall cosmesis, breast pain, breast edema, and
skin-color changes as significantly worse during
the first two years of follow-up in the group given
tamoxifen plus irradiation than in the tamoxifen
group; however, by the four-year assessment, the
differences were no longer significant. Physicians
also rated fibrosis or retraction as significantly
worse in the group given tamoxifen plus irradia-
tion than in the tamoxifen group one year and two
years after treatment; by four years after treatment,
however, the ratings in the two groups did not dif-
fer significantly.
As compared with the women in the tamoxifen
group, women in the group given tamoxifen plus
irradiation consistently rated breast pain as worse.
The women in this group also judged fibrosis and
retraction to be significantly worse during the first
two years after treatment; this difference had re-
solved by the four-year assessment.
Several large trials have shown that survival among
women with breast cancer is not influenced by the
addition of irradiation to partial mastectomy, al-
though irradiation does decrease the incidence of
ipsilateral recurrence.
 
1-5
 
 A meta-analysis of radia-
tion after lumpectomy or mastectomy has suggest-
ed that there may be an advantage in terms of
breast-cancer–specific survival; however, it found
no significant difference in overall mortality.
 
2
 
Breast cancer tends to be less aggressive and
more indolent in women who are 70 years of age or
older than in younger women. The rate of ipsilater-
al recurrence decreases with age, an effect likely to
be enhanced by tamoxifen.
 
9
 
 In addition, the pres-
ence of coexisting conditions
 
17
 
 and the fact that
these women have fewer years to live than younger
women
 
18
 
 shorten the time during which women
70 years of age or older are at risk for a recurrence.
Our results confirm earlier observations that ra-
diation therapy significantly improves local control
but not overall survival among women with breast
cancer. Although it is true that 99 percent of the
group given tamoxifen plus irradiation, as com-
pared with 96 percent of the tamoxifen group, were
free from local or regional recurrence at five years
(P<0.001), the clinical significance of this absolute
decrease of 3 percent must be considered critically.
Previous studies have suggested that lumpecto-
my is an option after local recurrence if irradiation
discussion
 
Table 2. Outcome.
Outcome
Tamoxifen
+ Irradiation
(N=317)
Tamoxifen
(N=319)
Total
(N=636)
 
no. of women
 
Recurrence
Any local or regional 2 16 18
Axilla 0 2 2
Ipsilateral breast alone 2 13 15
Ipsilateral breast + distant 0 1 1
Distant alone 7 6 13
Death from any cause 54 53 107
Death from breast cancer 3 3 6
 
Figure 2. Overall Survival.
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was not used in the initial therapy.
 
19
 
 Eight of the 14
women with breast recurrence in the tamoxifen
group underwent breast-conserving therapy. In the
group given irradiation plus tamoxifen, both wom-
en with a local recurrence required a mastectomy.
There was no discernible difference between the
groups in the likelihood of mastectomy after recur-
rence.
None of the women in the group given tamoxi-
fen plus irradiation had an axillary recurrence, and
there were no axillary recurrences among the 115
women in the tamoxifen group who had under-
gone axillary dissection. There were only 2 women
with axillary recurrences among the 204 women in
this group who had not undergone axillary dissec-
tion; in both, salvage therapy with axillary dissec-
tion was successful. These findings suggest that
axillary evaluation (by means of dissection or senti-
nel-node biopsy) has little value in women 70 years
of age or older who are receiving tamoxifen for
clinical stage I, estrogen-receptor–positive breast
cancer (an exception would be women for whom
chemotherapy is being considered on the basis of
the axillary status).
There was no significant difference in the rate of
distant recurrence between the two treatment
groups. As of September 2003, there had been only
14 distant recurrences, 7 in each group. There was
also no significant difference in survival between
the two groups. After a median follow-up of five
years, 107 women had died
 
.
 
 It should be empha-
sized that only six deaths (6 percent of all deaths)
were caused by breast cancer, reinforcing the no-
tion that older women die from causes other than
cancer.
Although breast irradiation is relatively well tol-
erated, it is not without adverse effects. In this
study, breast pain and skin fibrosis or retraction
were worse in women who had undergone breast
irradiation. In addition, physicians considered cos-
mesis, edema, and skin color worse among pa-
tients who received irradiation than among women
who did not, and women who received irradiation
reported significantly worse shoulder and arm stiff-
ness. These results are consistent with previous re-
ports.
 
20,21
 
In summary, among women 70 years of age or
older who have early, estrogen-receptor–positive
breast cancer, the addition of adjuvant radiation
therapy to tamoxifen does not significantly decrease
the rate of mastectomy for local recurrence, in-
crease the survival rate, or increase the rate of free-
dom from distant metastases. For these reasons,
tamoxifen alone is a reasonable choice for adjuvant
treatment in such women. Patients and their physi-
cians should weigh the slightly increased risk of
local recurrence against the cost, inconvenience,
and adverse effects of irradiation. The choice of
treatment should take into account the needs of the
patient. Both options appear to be appropriate for
women who are 70 years of age or older and who
have clinical stage I, estrogen-receptor–positive
cancers.
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* P values of 0.05 or less indicate significantly worse adverse effects in the group 
given tamoxifen plus irradiation than in the tamoxifen group. NS denotes a 
 
P value greater than 0.05.
 
Table 3. Evaluation of Treatment Effects by Physicians and Patients.*
Variable
At 4 Mo
(N=603)
At 1 Yr
(N=477)
At 2 Yr
(N=437)
At 4 Yr
(N=241)
 
P value
 
Physicians’ ratings
 
Overall cosmesis 0.01–0.05 0.01–0.05 ≤0.01 NS
Breast pain 0.01–0.05 0.01–0.05 NS NS
Chest-wall or shoulder pain NS NS NS NS
Arm or shoulder stiffness NS NS NS NS
Breast edema 0.01–0.05 0.01–0.05 0.01–0.05 NS
Skin-color changes 0.01–0.05 0.01–0.05 0.01–0.05 NS
Fibrosis or retraction NS 0.01–0.05 ≤0.01 NS
Arm edema NS NS NS NS
 
At 4 Mo
(N=616)
At 1 Yr
(N=457)
At 2 Yr
(N=422)
At 4 Yr
(N=240)
 
P value
 
Patients’ ratings
 
Overall cosmesis NS NS ≤0.01 NS
Breast pain 0.01–0.05 ≤0.01 ≤0.01 ≤0.01
Chest-wall or shoulder pain NS NS NS NS
Arm or shoulder stiffness 0.01–0.05 NS NS <0.01
Breast edema NS NS NS NS
Skin-color changes NS NS NS NS
Fibrosis or retraction 0.01–0.05 0.01–0.05 0.01–0.05 NS
Arm edema NS NS NS NS
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University Medical Center, Durham, N.C. — J. Crawford; Massachusetts General Hospital, Boston — M.L. Grossbard; Medical University of
South Carolina, Charleston — M. Green; Memorial Sloan-Kettering Cancer Center, New York — C. Hudis; Mount Sinai School of Medicine,
New York — L.R. Silverman; North Shore–Long Island Jewish Medical Center, Manhasset, N.Y. — D.R. Budman; Rhode Island Hospital,
Providence — W. Sikov; Roswell Park Cancer Institute, Buffalo, N.Y. — E. Levine; SUNY Upstate Medical University, Syracuse, N.Y. —
S.L. Graziano; Ohio State University Medical Center, Columbus — C.D. Bloomfield; University of Alabama Birmingham, Birmingham —
R. Diasio; University of California at San Diego, San Diego — S.L. Seagren; University of California at San Francisco, San Francisco —
A.P. Venook; University of Chicago Medical Center, Chicago — G. Fleming; University of Illinois Community Clinical Oncology Program,
Chicago — T. Lad; University of Maryland Greenebaum Cancer Center, Baltimore — M. Edelman; University of Massachusetts Medical
Center, Worcester — P. Bhargava; University of Missouri/Ellis Fischel Cancer Center, Columbia — M.C. Perry; University of Nebraska Med-
ical Center, Omaha — A. Kessinger; University of North Carolina at Chapel Hill, Chapel Hill — T.C. Shea; University of Tennessee, Mem-
phis — H.B. Niell; Vermont Cancer Center, Burlington — H.B. Muss; Wake Forest University School of Medicine, Winston-Salem, N.C. —
D.D. Hurd; Walter Reed Army Medical Center, Washington, D.C. — J.J. Drabeck; Washington University School of Medicine, St. Louis —
N. Bartlett; and Weill Medical College of Cornell University, New York — S. Wadler.
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